ZIOPHARM Oncology (ZIOP) stock is currently showing downward return of -7.38% throughout last week and witnessed decreasing return of -29.15% in one month period. The stock price decreased -51.08% in three months and dipped -34.68% for the last six months trading period.
ZIOP indicated a yearly performance of -61.17% while year-to-date (YTD) performance stood at -45.41%. The stock price moved with change of -54.80% to its 50 Day low point and changed -2.59% comparing to its 50 Day high point.
ZIOPHARM Oncology (ZIOP) stock price performed at a change of -19.73% from 20 day SMA and stands at a distance of -34.59% away from 50 day SMA. At present time the stock is moving -45.03% away to its 200-day moving average. It goes without saying that investors should not rely solely on any one technique. However, applying moving-average strategies in conjunction with portfolio diversification and prudent money management may reduce one’s risk substantially.
ZIOPHARM Oncology (ZIOP) finalized the Monday at price of $2.26 after traded 2255476 shares. The average volume was noted at 1333.05K shares while its relative volume was seen at 1.72. Short Ratio of stock is 26.62. ZIOPHARM Oncology is a part of Healthcare sector and belongs to Biotechnology industry.
The recent session disclosed a -2.59% downward lead over its 52-week stock price low and showed downward move of -66.12% over its 52-week high stock price. The stock price volatility remained at 5.81% in recent month and reaches at 6.84% for the week. The Average True Range (ATR) is also a measure of volatility is currently sitting at 0.16.
ZIOPHARM Oncology (ZIOP) reported down return of -3.00% return in last trading session. It is a positive indicator for investor portfolio value — when the price of a stock Investor owns goes up in value. On the other side it is not a negative indicator for Investor portfolio value — when the price of a stock Investor owns moves down in value.
The return on assets ratio of the Company was -68.50% while its return on investment ratio was 55.30%. Price to sales ratio was 69.9 . 41.50% shares of the company were owned by Institutional investors and Insider investors hold stake of 0.90%.
In the liquidity ratio analysis; current ratio was 7.2 . The stock’s RSI amounts to 23.41. The relative strength index (RSI) reflected overbought area when it is above 70 and notifies oversold level when it is below 30. The Beta factor, which is used riskiness of the security was 1.34.
ZIOPHARM Oncology (ZIOP)’s EPS growth Analysis:
Out of the important value indicator of stocks, EPS growth rate is most important. It will depend on the stock, the industry and the interest rates. Some stocks rarely if ever have high EPS, while others seem like they are always high. Some industries have lower average historical EPS than others as well. Also interest rates can affect EPS. EPS stands for earning per share. It is calculates as Net Profit/No. of Shares Outstanding. The term earnings per share (EPS) represents the portion of a company’s earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock.
ZIOPHARM Oncology (ZIOP) is estimating to achieve earnings per share (EPS) growth of 59.50% for this year while EPS growth expected to touch 21.20% for next year. The company reported EPS (ttm) of -0.54. Take a view on its past five year record, annual EPS growth rate was 15.30%.
Generally, companies with positive EPS are more highly valued than companies with negative EPS, and a novice investor should just stick to companies with long track records of profit making. But that is not to say that companies with negative EPS should be avoided. These stocks are extremely attractive to contrarian/special events/distressed securities investors. But it takes a remarkable amount of expertise and knowledge (don’t forget common sense) to be investing in these companies and being successful. Evaluating stocks to buy and sell can be a tricky business, even with all of the data available at your fingertips.